TSX Biotech Stocks to Watch (TSX.V: QPT) (TSX:ONC; NASDAQ:ONCY) (TSX.V:IMV) AEZS) (TSX: AEZ).; Innovative Ovarian Cancer Treatments

New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline. Stocks mentioned include Quest PharmaTech Inc. (TSX.V: QPT), Oncolytics (TSX:ONC; NASDAQ:ONCY) , Immunovaccine, Inc. (TSX.V:IMV) and Aeterna Zentaris Inc. (AEZS) (TSX: AEZ).

There are 17,000 women living with ovarian cancer in Canada. It is estimated that this year in Canada, 2,600 women will be newly diagnosed with ovarian cancer. Ovarian cancer is the 5th most common cancer for women and is the most fatal women's cancer, says Ovarian Cancer Canada.
According to reported statistics, more than 22,000 women are diagnosed with ovarian cancer in the United States annually, and more than 12,000 die each year.
In February news reports said, "As many as one in four hundred women test positive for the BRCA-1 gene, often called the "breast cancer gene."
They have not only a significantly increased risk for breast cancer, but also for ovarian cancer.”
http://www.wlbz2.com/story/news/nation/2014/03/23/6788983/
Leading U.S. biotech stocks have had a massive bull run this year, although recently the sector has had a correction on concerns of valuations. However some of the smaller microcap stocks have not seen the same volatile trading patterns.
For investors looking at TSX biotech stocks and life sciences stocks, a recently released interview in the Life Sciences Report (TSLR) with Roadmap Capital explains the difference in valuations in US and TSX biotech stocks best.
"TLSR: Why invest primarily in Canadian companies? If you were exclusively a resource investor, and looking for deep value as well as growth, this is understandable, but in the life sciences sector, where the goal is huge growth, why limit yourself to Canadian stocks? Is it about tax advantages? National pride?
HC: I should point out that the new fund has made investments in the U.S. already, and will continue to do so. But we are focusing primarily in Canada. Frankly, it's about where we see the best opportunities and risk/reward ratio. There's no shortage of innovation in Canada, but the long, drawn-out bear market that the Canadian tech and healthcare sectors went through for much of the last decade has left many interesting companies valued at levels far below what is available in other countries. To give you an example, we're putting money into a company with a $2.5M pre-money valuation. Comparable companies in the States would be valued in the $30-40M pre-money range currently. And we have invested a small amount of money into a private stem cell company called Hemostemix. It is raising money at a $25M pre-money valuation, when its best public comparables in the U.S. trade at valuations in the $200—400M range. It comes down to where we see the best valuation opportunities and risk/reward for our investors right now. - "
Source : http://www.equities.com/editors-desk/stocks/healthcare/apply-market-savvy-to-bear-market-debris-uncover-biotech-treasures-cleland-and-ireland cPhase 2 biotech tsx ovarian cancer co's
Sector Snapshot : Ovarian Cancer Treatment
Quest PharmaTech Inc.'s ( TSX.V: QPT).lead product, Oregovomab is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients.
From a previous interview with Investorideas.com, Madi R. Madiyalakan, Ph.D., Chief Executive Officer, said "Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. We are also initiating a clinical trial using Oregovomab in combination with an immuno-adjuvant, Hiltonol® (TLR3 agonist), with standard chemotherapy. Oregovomab is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers. "
Six month chart:
Oncolytics (TSX: ONC; NASDAQ:ONCY)
Oncolytics Biotech Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications. Ovarian cancer : OG-0186H (NCI / GOG Trial) Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel for Patients with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer US- status is ongoing.
Six month chart:
Immunovaccine, Inc. (TSX.V: IMV)
According to the company's financial report released March 17th, "During 2013, scientists provided compelling evidence that the human immune system could be trained to destroy cancer cells," said Dr Marc Mansour, chief operating officer. "These findings support the idea that immunotherapies have the potential to shift cancer from a life threatening disease to a chronic and manageable condition.
"Several large pharmaceutical companies also announced during the year that vaccines will play an important role in the development of their cancer therapy programs. These industry trends parallel our own approach to the development of therapeutic cancer vaccines. With our planned trials in ovarian cancer, glioblastoma and breast cancer expected to begin this year, IMV is well placed to participate in this rapidly evolving industry."
Highlights of 2013 and First Quarter of 2014

• DPX-Survivac - Positive data from Immunovaccine's completed Phase I study were presented at multiple venues throughout the year, including the 2013 ASCO annual meeting. We believe that these findings represent some of the strongest immune responses against a cancer target seen to date.

Based on these promising data, Canada's NCIC Clinical Trials Group (NCIC) agreed to sponsor and conduct a randomized Phase II study of DPX-Survivac in patients with advanced ovarian cancer. We expect this study to be initiated in 2014 with results available in 2017. Immunovaccine also signed an agreement with the University of Rome for a multicenter Phase II study of DPX-Survivac in glioblastoma patients. The study is expected to begin in 2014 and its costs will be assumed by this University.

• DPX-0907 - Immunovaccine agreed to allow use of DPX-0907 in a Phase I/II study of breast and ovarian cancer patients at the Busto Arsizio Hospital in Italy. The study, which will be funded by Busto Arsizio, is expected to be initiated in 2014.

Six month chart :
Aeterna Zentaris Inc. (AEZS) (TSX: AEZ)  is a biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. Their pipeline includes Zoptarelin doxorubicin for Ovarian and prostate cancer, currently in Phase 11. Zoptarelin doxorubicin is a targeted cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by the LHRH receptor-positive tumors. The binding of conjugate molecule zoptarelin doxorubicin to cancerous cells that express these receptors results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be more effective and have less side-effects than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.
Six month chart
TSX Life Sciences Snapshot
Life Sciences Markets at a Glance – YTD February 28, 2014

February   2014	TSX Venture (TSXV)	TSX	TSXV and TSX
Number of Issuers	69	39	108
QMV (C$)	2,153,038,500	63,319,048,526	65,472,087,027
New Listings	2	-	2
Equity Capital Raised (C$)	126,738,564	10,823,900	137,562,464
Number of Financings	18	2	20
Volume Traded	295,773,521	238,949,246	534,722,767
Value Traded (C$)	162,114,369	3,263,237,459	3,425,351,827
# of Trades	82,324	277,538	359,862

http://www.tmx.com/en/listings/sector_profiles/life_sciences.html
According to the TSX, nearly $3 billion of equity capital was raised by life sciences companies on TSX and TSXV in 2013.
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target

SAN DIEGO - March 19, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brainderived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.

"Building on our proprietary method to identify, quantitate and characterize brain-derived exosomes, we now have the ability to detect this aggressive cancer early and aid in its treatment," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. The Aethlon Hemopurifier® is a first in class medical device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that promote cancer progression and suppress the immune system of cancer patients. Aethlon is currently preparing to launch the first FDA approved clinical study of Hemopurifier® therapy in the United States. ESI was established by Aethlon to develop non-invasive exosome-based "liquid biopsies" that diagnose and monitor acute and chronic disease conditions.
GBM represents the most common, per capita costly and uniformly lethal primary brain tumor. GBM comprise 23% of primary brain tumors in the US and is the most commonly diagnosed brain tumor in adults aged 45-74 with men being more frequently diagnosed than women. The prognosis remains poor despite aggressive treatment modalities. Over the past decade, a median survival time of 12 months has only been marginally improved to 14.6 months as a result of advances in chemo/radiation and the use of molecularly targeted agents. Beyond being a candidate target for Hemopurifier® therapy, the discovery of circulating GBM-exosomes offers a potential new paradigm in GBM clinical management through a platform technology to predict tumor regression or progression.
"The ability to characterize disease specific exosomes in circulation will enable improved diagnosis to identify type and grade of these most challenging of brain tumors and may additionally help to advance novel treatment strategies," stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
To date, there have been two critical barriers to successful GBM treatment. First, there currently is no method for evaluating the dynamic changes in GBM during therapy. Standard imaging approaches do not provide metrics of tumor-specific genetic/phenotypic changes and operative information is expensive, potentially morbid and limited by errors in topographic sampling. Second, clinicians, lacking tumor-specific parameters, are unable to effectively monitor responses to therapy over short time frames. These limitations are derived from the difficulty in obtaining repeated biopsies of tumor tissue, and the confounding effects on tumor MRI of necrosis, inflammation, surgical artifact and edema. Additionally, the appearance of GBM by current imaging techniques is not specific, since other lesions such as abscess, metastasis, and other entities may have a similar appearance. As a result, clinicians have not been able to adequately evaluate therapeutic agents designed to target GBM. The objective of the Aethlon-ESI team is to extend and improve GBM patient quality of life by resolving the clinical challenges of monitoring patient response to both established and candidate therapies.
Earlier this month, the Aethlon-ESI research team disclosed that it was also to isolate brain-specific biomarkers that could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). The research studies provided evidence that exosomes can serve as a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce Brain Research Discoveries

SAN DIEGO - March 5, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

The research studies provided evidence that exosomes can serve as a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
"This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.
"With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death," stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.
"An exosome-based liquid biopsy that could identify the early onset of Alzheimer's disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices," stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.
Therapeutic Application and Patent Application
The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the "peripheral sink" theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, "Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies."
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Agreement with DaVita Clinical Research

SAN DIEGO - February 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients.

DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners, DCR has access to one third of the total US end-stage renal disease (ESRD) patient population and maintains a network that exceeds 150 investigative physicians practices at more than 250 clinical sites.
Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. Under the feasibility study protocol, Aethlon is to enroll ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease indications.
"Not long after the FDA had cleared our IDE, we were presented an opportunity to advance a clinical relationship with DaVita Clinical Research,” stated Aethlon Chairman and CEO, Jim Joyce. "As a result, we have transitioned our clinical plan from working with a single-site institute to working with a single institute that has a multitude of clinical sites across the United States. Beyond maintaining the resources necessary to advance our feasibility study, DaVita's proven extracorporeal expertise, patient accrual capabilities and expansive clinical infrastructure provide a foundation to support our long-term vision of treating a variety of infectious disease and cancer indications."
Aethlon further disclosed that the DCR agreement was entered into on a non-exclusive basis and is pending the completion of a definitive agreement, which will include a work order describing the full scope of services to be provided by DCR to Aethlon Medical.
DaVita Clinical Research is a wholly owned subsidiary of DaVita HealthCare Partners (NYSE:DVA), a Fortune 500 company and parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States and abroad, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of December 31, 2013, DaVita operated or provided administrative services at 2,074 outpatient dialysis centers in the United States serving approximately 168,000 patients, and at 73 centers in ten countries outside of the United States. HealthCare Partners(R) manages and operates medical groups and affiliated physician networks in California, Nevada, Florida, Arizona and New Mexico in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of December 31, 2013, HealthCare Partners provided integrated care management for approximately 765,000 managed care patients. For more information, please visit DaVitaHealthCarePartners.com.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY, NYSE), (CELG)

Point Roberts, WA, New York, NY - February 26, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Companies include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE: LLY) and Celgene (NASDAQ::CELG).

According to the Pancreatic Cancer Action Network "Pancreatic cancer is currently the fourth leading cause of cancer death in the United States, and is anticipated to become the second by 2020.”
In their fact sheet they also note " Pancreatic cancer is one of the nation's deadliest cancers with a five-year relative survival rate of just 6 percent. An estimated 73 percent of patients will die in the first year of diagnosis. In 2014, an estimated 46,420 people will be diagnosed with pancreatic cancer in the United States, and approximately 39,590 will die from the disease.”
Decision Resources (http://www.decisionresources.com/),one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents—Celgene (NASDAQ::CELG)/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.
The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
NewLink Genetics (NASDAQ: NLNK) has been of the top gainers for 2014,gaining over 90%.NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.
Their product, RAlgenpantucel-L is an investigational HyperAcute™ immunotherapy for pancreatic cancer. The product consists of 2 pancreatic cancer cell lines (HAPa-1 and HAPa-2) that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules.1 Upon injection into the patient, the alpha-gal stimulates an immune response against pancreatic cancer-specific antigens in the tumor cell lines. The patient's immune system then targets its own pancreatic cancer cells, destroying them.1 In the adjuvant setting, the immune response targets and eradicates residual tumor cells in conjunction with chemotherapy and chemoradiation.1,2
Algenpantucel-L is currently being studied in combination with standard of care in two phase 3 trials:
Last fall the company reported greater than expected responses to follow-on chemotherapy after treatment with algenpantucel-L or tergenpumatucel-L HyperAcute immunotherapy. Three pancreatic cancer patients were followed for response to subsequent salvage chemotherapy treatment after progressing on algenpantucel-L therapy. All three patients experienced durable (12-36 months), complete responses.
Sunshine Biopharma Inc. ( OTCBB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, recently announced that it is targeting pancreatic cancer as second indication for its leading compound, Adva-27a.
As previously announced, Adva-27a was found to be effective at killing Pancreatic Cancer Cells in vitro. Based on initial data, the company is now advancing research using Adva-27a for pancreatic cancer treatment.
The initial study, as reported in June 2013, was carried out in the very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
The Company also announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma's parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.
"Conducting tests in pancreatic cancer xenograft models is the next step in our preparations for doing parallel breast cancer and pancreatic cancer clinical trials of Adva-27a," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Pancreatic cancer is an extremely aggressive form of cancer with essentially no effective treatment options available today. We are heartened by the prospects that Adva-27a could become an effective therapy for patients suffering this deadly form of cancer."
According to Global Industry Analysts, Inc. in their recent report, "Eli Lilly's (LLY:NYSE) Gemzar (Gemcitabine) is the current gold standard of care for locally advanced and metastatic disease, with a dominance that is undisputed despite a median survival of less than 6 months and rate of one-year survival of around 18%, as stated by the new market research report on Pancreatic cancer drugs. Though the odds of survival are somewhat better in other forms of cancer, the rate of five-year survival for the most common form of pancreatic cancer, Adenocarcinoma of the pancreas is less than 5%, with majority of patients surviving just a few months. "
www.Investorideas.com - Big ideas for Global Investors
Investorideas.com is a global news source and resource base for investors following tech stocks, biometric stocks, water stocks, biotech stocks, energy stocks, mining stocks, renewable energy stocks, nanotech and Latin American stocks.
Follow Investorideas.com on Twitter  
Follow Investorideas.com on Facebook  
Follow Investorideas.com News on Linkedin.com/today
Sign up for free news alerts and get free research tools:
http://www.investorideas.com/Resources/Newsletter.asp
Join us and become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investor ideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure investor ideas has been compensated with 144 shares for news and content publication ( 100,000 per three month period)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY), (CELG)

Point Roberts WA, New York, NY - February 19, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Stocks mentioned include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE:LLY) and Celgene (NASDAQ:CELG).

Decision Resources ( http://www.decisionresources.com/ ),one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents-Celgene (NASDAQ:CELG)/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.
The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
NewLink Genetics (NASDAQ:NLNK) has been of the top gainers for 2014,gaining over 90%.NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.
Their product, RAlgenpantucel-L is an investigational HyperAcute™ immunotherapy for pancreatic cancer. The product consists of 2 pancreatic cancer cell lines (HAPa-1 and HAPa-2) that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules.1 Upon injection into the patient, the alpha-gal stimulates an immune response against pancreatic cancer-specific antigens in the tumor cell lines. The patient’s immune system then targets its own pancreatic cancer cells, destroying them.1 In the adjuvant setting, the immune response targets and eradicates residual tumor cells in conjunction with chemotherapy and chemoradiation.1,2.
Algenpantucel-L is currently being studied in combination with standard of care in two phase 3 trials:
Last fall the company reported greater than expected responses to follow-on chemotherapy after treatment with algenpantucel-L or tergenpumatucel-L HyperAcute immunotherapy. Three pancreatic cancer patients were followed for response to subsequent salvage chemotherapy treatment after progressing on algenpantucel-L therapy. All three patients experienced durable (12-36 months), complete responses.
Sunshine Biopharma Inc. ( OTCBB:SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, recently announced that it is targeting pancreatic cancer as second indication for its leading compound, Adva-27a.
As previously announced, Adva-27a was found to be effective at killing Pancreatic Cancer Cells in vitro. Based on initial data, the company is now advancing research using Adva-27a for pancreatic cancer treatment.
The initial study, as reported in June 2013, was carried out in the very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
According to Global Industry Analysts, Inc. in their recent report, "Eli Lilly's (NYSE:LLY) Gemzar (Gemcitabine) is the current gold standard of care for locally advanced and metastatic disease, with a dominance that is undisputed despite a median survival of less than 6 months and rate of one-year survival of around 18%, as stated by the new market research report on Pancreatic cancer drugs. Though the odds of survival are somewhat better in other forms of cancer, the rate of five-year survival for the most common form of pancreatic cancer, Adenocarcinoma of the pancreas is less than 5%, with majority of patients surviving just a few months. "
www.Investorideas.com - Big ideas for Global Investors
Investorideas.com is a global news source and resource base for investors following tech stocks, biometric stocks, water stocks, biotech stocks, energy stocks, mining stocks, renewable energy stocks, nanotech and Latin American stocks.
Follow Investorideas.com on Twitter  
Follow Investorideas.com on Facebook  
Follow Investorideas.com News on Linkedin.com/today
Sign up for free news alerts and get free research tools:
http://www.investorideas.com/Resources/Newsletter.asp
Join us and become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investor ideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure investor ideas has been compensated with 144 shares for news and content publication ( 100,000 per three month period)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 -   Source – www.Investorideas.com

Biotech News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) BEGINS CONSTRUCTION OF MOUSE XENOGRAFT MODELS FOR PANCREATIC CANCER TO ADVANCE Adva-27a AS A TREATMENT FOR THIS DEADLY FORM OF CANCER

Montreal, Quebec, Canada - February 14, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. The work is being conducted in collaboration with Sunshine Biopharma’s parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.

"Conducting tests in pancreatic cancer xenograft models is the next step in our preparations for doing parallel breast cancer and pancreatic cancer clinical trials of Adva-27a," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Pancreatic cancer is an extremely aggressive form of cancer with essentially no effective treatment options available today. We are heartened by the prospects that Adva-27a could become an effective therapy for patients suffering this deadly form of cancer."
About Pancreatic Cancer
Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. According to the American Cancer Society, an estimated 45,220 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013. Approximately 95% of pancreatic tumors are of the adenocarcinoma type, arising within the exocrine component of the pancreas where various digestive enzymes are produced. The remaining 5% arise from the islet cells and are classified as neuroendocrine tumors. The islet cells produce important hormones such as insulin, which regulates the sugar levels in the blood. Both types are very aggressive and respond poorly to standard chemotherapy drugs. In contrast to the downward trend in death rates for most major cancer types, death rates due to pancreatic cancer have been slowly increasing in the U.S. over the past decade. This, together with the lack effective therapy, underscores the need for major new drug development efforts to reverse these trends.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.